RO7435846

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung CancerResected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer

Phase 3

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

RecruitingCTIS2024-518365-10-00

F. Hoffmann-La Roche AGPreviously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

Start: 2025-10-28Target: 282Updated: 2026-01-13

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

Not yet recruitingCTIS2025-524263-21-01

F. Hoffmann-La Roche AGResected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer

Target: 80Updated: 2026-08-28